,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['solid tumor', 'enhertu']
it s not so long ago that some experts questioned if antibody-drug conjugates would have a future in solid tumor indications. the hype cycle at its best. good to see that solid science in the end prevails: enhertu news at #asco22 
MedChem @Merckgroup; drug discovery, oncology, targeted protein degradation, chemical probes; CDU, Hannover96, literature, traveling; my own views ????????????